[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-430759-en":59,"doc-seo-430759-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},430759,549768072016,"WPS_1786070896","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma - a systematic review and meta-analysis","This systematic review and meta-analysis evaluates efficacy and safety of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Studies were identified through searches of PubMed and Web of Science up to November 29, 2023, including cohort studies and single-arm clinical trials. Thirty-seven studies were pooled, comparing liso-cel, axi-cel, and tisa-cel across survival, response, and adverse events, showing liso-cel’s generally favorable balance while noting data limitations for real-world evidence.","TherapeuTic advances in  \nhematology Meta-analysis  \nEfficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/ refractory large B-cell lymphoma: a systematic review and meta-analysis  \nQiang Li, Shenghua Xu, Yun Zhong, Peng Rao, Hui Huang andYan Huang  \nAbstract  \nBackground: Individuals diagnosed with relapsed or refractory large B-cell lymphoma (R/RLBCL) typically exhibit a dismal prognosis when treated with conventional therapeutic modalities. CD19—targeted chimeric antigen receptor T (CAR-T) cell therapy has brought about a paradigm shift in the treatment paradigm of this disease. Nevertheless, a comprehensive assessment of the efficacy and safety profiles of diverse CAR-T products (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)) is imperative.  \nObjective: This systematic review aims to systematically summarize and evaluate the efficacy and safety of CAR T-cell therapies for R/R LBCL through systematic review and meta-analytic approaches.  \nDesign: This is a systematic review and meta-analysis.  \nData sources and methods: Relevant studies were identified by systematically searching PubMed and Web of Science until November 29, 2023. Cohort studies and clinical trials were incorporated, with the inclusion of single-arm studies. CAR T-cell therapies are involved intisa-cel, axi-cel, and liso-cel. Proportions and their 95% confidence intervals were calculated using standard meta-analytic approaches.  \nResults: Thirty-seven studies were included in meta-analyses, liso-cel demonstrated equivalent overall survival rates (70 .3%) to axi-cel (65 . 6%) at 12 months post-treatment, whereas tisa-cel was 48.0% . Objective response rate for liso-cel was comparable to axi-cel (79.0% vs 76.8%, pmeta-regression = 0.74), both of which were notably higher than those observed for tisa-cel (58.3%, both pmeta-regression \u003C 0.05) . Regarding safety assessments, liso-cel exhibited the lowest cytokine release syndrome rate at 43. 0%, followed by tisa-cel at 70. 9%, and axi-celat 87. 9% . However, tisa-cel had the lowest incidence of neurologic events (14 . 9%), in contrast to liso-cel (21 . 1%) and axi-cel (52 .3%) .  \nConclusion: Based on the available evidence, liso-cel has shown promising efficacy and a manageable safety profile in patients with R/R LBCL, when compared to axi-cel and tisa-cel. However, real-world data on liso-cel are limited.  \nPlain language summary  \nA meta-analytic review for Chimeric antigen receptor T-cell therapy in relapsed/ refractory large B-cell lymphoma  \nThis study provides a comprehensive evaluation of three CAR T-cell therapies for treating aggressive lymphoma that has returned or stopped responding to treatment. The analysis shows that lisocabtagene maraleucel (liso-cel) performed similarly to axicabtagene  \nTherAdv Hematol 2026, Vol. 17: 1–31  \nDOI: 10. 1177/ 20406207251407511 © The Author(s), 2026.  \nArticle reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nYan Huang Hui Huang  \nDepartment of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi 330029, China  \n[huangyan_333@163.com](huangyan_333@163.com)[ ](huangyan_333@163.com)[1364961938@qq.com](1364961938@qq.com)  \nQiang Li Shenghua Xu Yun Zhong  \nDepartment of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China  \nPeng Rao  \nDepartment of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital,  \nNanchang, Jiangxi, China Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China  \n[journals.sagepub.com/home/tah](journals.sagepub.com/home/tah) 1  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  \n([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduc","cbCaignWRHuqVoYL","https://ap.wps.com/l/cbCaignWRHuqVoYL","pdf",8070132,31,"English","en",105,"# Abstract\n## Background\n## Objective\n## Design\n## Data sources and methods\n## Results\n## Conclusion\n## Plain language summary\n## Keywords\n# Introduction","[{\"question\":\"What patient population does this systematic review focus on?\",\"answer\":\"Patients diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL).\"},{\"question\":\"Which CAR T-cell products are compared in the analysis?\",\"answer\":\"The review compares lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel).\"},{\"question\":\"What overall safety and efficacy signals are reported across the therapies?\",\"answer\":\"Liso-cel shows promising efficacy with the lowest cytokine release syndrome rate, while neurologic events are lowest for tisa-cel; overall response and survival outcomes are compared at about 12 months post-treatment.\"}]","Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma - a systematic review and meta-analysis | PDF",1790653633,78,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-in-relapsedrefractory-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":35,"@type":94,"position":99},"https://docshare.wps.com/document/healthcare/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-in-relapsedrefractory-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/430759/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-therapy-in-relapsedrefractory-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/430759.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":119,"interactionType":120,"userInteractionCount":44},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"What patient population does this systematic review focus on?","Question",{"text":129,"@type":130},"Patients diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL).","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"Which CAR T-cell products are compared in the analysis?",{"text":134,"@type":130},"The review compares lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel).",{"name":136,"@type":127,"acceptedAnswer":137},"What overall safety and efficacy signals are reported across the therapies?",{"text":138,"@type":130},"Liso-cel shows promising efficacy with the lowest cytokine release syndrome rate, while neurologic events are lowest for tisa-cel; overall response and survival outcomes are compared at about 12 months post-treatment.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790866989]